HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Suzhou Nanomicro Technology  / Equity Capital Markets

Recently, <a href="https://www.smartkarma.com/entities/suzhou-nanomicro-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:33272:1" rel="noopener">Suzhou Nanomicro Technology (1778887D CH)</a> was approved to list on China SSE STAR Market. NanoMicro’s products cover a broad spectrum of applications including high performance Chromatography Media, solid phase extraction (SPE) sorbents, Particle Size Standards, Magnetic Particles, LCD Spacers, ACF Conductive Particles, and various other micro particles. In fact, the biopharmaceutical industry is even more inseparable from microsphere technology, and chromatography packing/chromatographic medium is widely used for isolation and purification. In the past, the market was highly monopolized by foreign manufacturers, but NanoMicro successfully broke through the blockade on techniques. At present, NanoMicro is one of the few companies in the world that can simultaneously produce inorganic and organic high-performance nanoparticles on a large scale, which is an investment opportunity that cannot be missed.

Recently, Suzhou Nanomicro Technology (1778887D CH) was approved to list on China SSE STAR Market. NanoMicro’s products cover a broad spectrum of applications including high performance Chromatography Media, solid phase extraction (SPE) sorbents, Particle Size Standards, Magnetic Particles, LCD Spacers, ACF Conductive Particles, and various other micro particles. In fact, the biopharmaceutical industry is even more inseparable from microsphere technology, and chromatography packing/chromatographic medium is widely used for isolation and purification. In the past, the market was highly monopolized by foreign manufacturers, but NanoMicro successfully broke through the blockade on techniques. At present, NanoMicro is one of the few companies in the world that can simultaneously produce inorganic and organic high-performance nanoparticles on a large scale, which is an investment opportunity that cannot be missed.

Pre-IPO Suzhou NanoMicro Tech - A Good Company You Don't Want to Miss

Clover Biopharmaceuticals / Equity Capital Markets

On April 23, 2021, <a href="https://www.smartkarma.com/entities/clover-biopharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:33029:1" rel="noopener">Clover Biopharmaceuticals (CBL HK)</a> filed a prospectus with the Hong Kong Stock Exchange in preparation for a listing in Hong Kong. Since the beginning of the 21st century, with the continuous emergence of innovative biotechnology enterprises in China, many research-based type of entrepreneurs have started their own businesses, such as Wang Xiaodong from <a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK)</a>, Yu Dechao from <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, Du Ying from <a href="https://www.smartkarma.com/entities/zai-lab-ltd" target="_blank" data-smartkarma-citation="entities:25877:1" rel="noopener">Zai Lab Ltd (ZLAB US)</a>, etc. Liang Peng, the Founder of Clover Biopharmaceutical, also has an impressive background. He founded the Company in Chengdu in 2007 with his exclusive Trimer-Tag technology platform. The other core members of the Company include China's top pharmaceutical “think tank” such as Dr. Xiaodong Wang and Dr. Jianwei Zhu. So, are there any other highlights besides the outstanding team? This insight mainly analyzed the core technology platform and the core product candidates in the pipeline.

On April 23, 2021, Clover Biopharmaceuticals (CBL HK) filed a prospectus with the Hong Kong Stock Exchange in preparation for a listing in Hong Kong. Since the beginning of the 21st century, with the continuous emergence of innovative biotechnology enterprises in China, many research-based type of entrepreneurs have started their own businesses, such as Wang Xiaodong from BeiGene Ltd (6160 HK), Yu Dechao from Innovent Biologics Inc (1801 HK), Du Ying from Zai Lab Ltd (ZLAB US), etc. Liang Peng, the Founder of Clover Biopharmaceutical, also has an impressive background. He founded the Company in Chengdu in 2007 with his exclusive Trimer-Tag technology platform. The other core members of the Company include China's top pharmaceutical “think tank” such as Dr. Xiaodong Wang and Dr. Jianwei Zhu. So, are there any other highlights besides the outstanding team? This insight mainly analyzed the core technology platform and the core product candidates in the pipeline.

Pre-IPO Clover Biopharmaceuticals - Insights on the Core Technology and Product Candidates

Equity Bottom-Up

Shanghai Junshi Biosciences  / Equity Bottom-Up

Last month, <a href="https://www.smartkarma.com/entities/shanghai-junshi-bioscience-a" target="_blank" data-smartkarma-citation="entities:31070:1" rel="noopener">Shanghai Junshi Bioscience (688180 CH)</a> released the performance announcement in 2020. Junshi is expected to achieve the revenue in 2020 of RMB1.595 billion, up 105.77% YoY. The Company's net loss attributed to shareholders could reach RMB1.672 billion, up 123.8% YoY. Meanwhile, the R&amp;D expenses are expected to reach RMB1.824 billion in 2020, up 92.79% YoY, which even exceeded the total revenue in 2020. It is also worth mentioning that the moment of glory of Junshi seems to be when it was listed on the SSE STAR Market in July 2020, with the market value of about RMB150 billion, and then its share price went all the way down to hit the bottom in December 2020 at RMB 64.8/share. On March 19, 2021, Junshi’s market value was RMB79 billion, down about 50% since July 2020. So could Junshi turn things around?

Last month, Shanghai Junshi Bioscience (688180 CH) released the performance announcement in 2020. Junshi is expected to achieve the revenue in 2020 of RMB1.595 billion, up 105.77% YoY. The Company's net loss attributed to shareholders could reach RMB1.672 billion, up 123.8% YoY. Meanwhile, the R&amp;D expenses are expected to reach RMB1.824 billion in 2020, up 92.79% YoY, which even exceeded the total revenue in 2020. It is also worth mentioning that the moment of glory of Junshi seems to be when it was listed on the SSE STAR Market in July 2020, with the market value of about RMB150 billion, and then its share price went all the way down to hit the bottom in December 2020 at RMB 64.8/share. On March 19, 2021, Junshi’s market value was RMB79 billion, down about 50% since July 2020. So could Junshi turn things around?

Shanghai Junshi Bioscience - Here Are the Challenges

Bio-Thera Solutions Ltd / Equity Bottom-Up

In the first quarter of 2021, following the failure of the BAT8001 phase III clinical trial, <a href="https://www.smartkarma.com/entities/bio-thera-solutions-ltd" target="_blank" data-smartkarma-citation="entities:29127:1" rel="noopener">Bio-Thera Solutions Ltd (688177 CH)</a> announced the suspension of R&amp;D of two other projects in the pipeline, BAT8003 and BAT1306. It is estimated that Bio-Thera has invested about RMB340 million in these three projects. Currently, Bio-Thera has only one product (Qletli) on the market. In the financial reports of 2020, the revenue was RMB185 million and Qletli contributed about RMB183 million, almost the entire revenue of the Company. Meanwhile, the net loss in 2020 was RMB513 million, and the Company has been suffering from losses for five consecutive years. So, what's next for Bio-Thera after R&amp;D setbacks and years of losses?

In the first quarter of 2021, following the failure of the BAT8001 phase III clinical trial, Bio-Thera Solutions Ltd (688177 CH) announced the suspension of R&amp;D of two other projects in the pipeline, BAT8003 and BAT1306. It is estimated that Bio-Thera has invested about RMB340 million in these three projects. Currently, Bio-Thera has only one product (Qletli) on the market. In the financial reports of 2020, the revenue was RMB185 million and Qletli contributed about RMB183 million, almost the entire revenue of the Company. Meanwhile, the net loss in 2020 was RMB513 million, and the Company has been suffering from losses for five consecutive years. So, what's next for Bio-Thera after R&amp;D setbacks and years of losses?

Bio-Thera Solutions (688177.CH) - What's Next for Bio-Thera After R&D Setbacks and Years of Losses?

Genor Biopharma Holdings  / Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/jhbp-cy-holdings-ltd" target="_blank" data-smartkarma-citation="entities:29201:1" rel="noopener">JHBP (Genor) (6998 HK)</a> is a biopharmaceutical company that focuses on the R&amp;D and commercialization of oncology and autoimmune drugs, with a number of products in the late stage of clinical development and close to commercialization. Perhaps because of such characteristics, Genor is favored by reputable investment institutions such as Hillhouse Capital, Temasek, etc.. However, the stock price of Genor reached its peak when it was listed. It only rose in the first two days and then fell all the way. By March 9th, 2021, the closing price of Genor was HK$16.74/share, which was about 50% lower than the peak of HK$32.2/share at the beginning of listing. So, why is that?

JHBP (Genor) (6998 HK) is a biopharmaceutical company that focuses on the R&amp;D and commercialization of oncology and autoimmune drugs, with a number of products in the late stage of clinical development and close to commercialization. Perhaps because of such characteristics, Genor is favored by reputable investment institutions such as Hillhouse Capital, Temasek, etc.. However, the stock price of Genor reached its peak when it was listed. It only rose in the first two days and then fell all the way. By March 9th, 2021, the closing price of Genor was HK$16.74/share, which was about 50% lower than the peak of HK$32.2/share at the beginning of listing. So, why is that?

Genor Biopharma (6998.HK) - Here Is Why the Stock Price Decreased by About 50%

China

Zhejiang Hisun Pharmaceutical Co. Ltd. develops and manufactures pharmaceutical products. The Company's products include anti-tumor, anti-parasite, cardiovascular, and anti-infection drugs.

Zhejiang Hisun Pharmaceutical Co, Ltd. (600267 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zhejiang Hisun Pharmaceutical Co, Ltd. (600267 CH)

Pre-IPO Suzhou NanoMicro Tech - A Good Company You Don't Want to Miss

This article analyzed NanoMicro in terms of the market potential, industry characteristics, business prospects, profitability and potential...

Xinyao (Criss) Wang

Pre-IPO Clover Biopharmaceuticals - Insights on the Core Technology and Product Candidates

The article analyzed Clover's core technology platform, COVID-19 vaccine and SCB-808 in pipeline,future challenge on competition and potential...

Xinyao (Criss) Wang

Shanghai Junshi Bioscience - Here Are the Challenges

The article analyzed the concerns and challenges that Junshi has to face in terms of PD-1, COVID-19 antibody drug, other products in the pipeline...

Xinyao (Criss) Wang

Bio-Thera Solutions (688177.CH) - What's Next for Bio-Thera After R&D Setbacks and Years of Losses?

The article analyzed the concerns after the suspension of R&D of its three core products, the challenges of its listed product Qletli,and also the...

Xinyao (Criss) Wang

Genor Biopharma (6998.HK) - Here Is Why the Stock Price Decreased by About 50%

This article analyzed the concerns of Genor Biopharma in terms of core products, competitive landscape, industry characteristics and the potential...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)